2024-21432. Allergan, Inc., et al.; Withdrawal of Approval of Nine Abbreviated New Drug Applications
Table 1—ANDAs for Which Approval Is Withdrawn
Application No. Drug Applicant ANDA 062452 Gentamicin Sulfate solution/drop, Equivalent to (EQ) 0.3% base Allergan, Inc., 2525 Dupont Dr., P.O. Box 19534, Irvine, CA 92612. ANDA 064124 Cefuroxime Sodium injectable, EQ 7.5 grams (g) base/vial ACS Dobfar S.p.A., U.S. Agent Interchem Corp., 120 Route 17 North, Paramus, NJ 07652. ANDA 077151 Milrinone Lactate injectable, EQ 40 milligrams (mg) base/200 milliliters (mL) (EQ 0.2 mg base/mL) EQ 20 mg base/100 mL (EQ 0.2 mg base/mL) Woodward Pharma Services, LLC, 47220 Cartier Dr., Suite A, Wixom, MI 48393. ANDA 079032 Ondansetron Hydrochloride preservative free injectable, EQ 2 mg base/mL American Regent, Inc., 5 Ramsey Rd., Shirley, NY 11967. ANDA 079075 Fentanyl Citrate tablet, EQ 0.1 mg base, EQ 0.2 mg base, EQ 0.4 mg base, EQ 0.6 mg base, and EQ 0.8 mg base Watson Laboratories, Inc., (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Bldg. A, Parsippany, NJ 07054. ANDA 206155 Olanzapine tablet, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg Indoco Remedies Ltd., U.S. Agent RegCon Solutions, LLC, 9920 Pacific Heights Blvd., Suite 250, San Diego, CA 92121. ANDA 206204 Piperacillin Sodium and Tazobactam Sodium injectable, EQ 12 gm base/vial, EQ 1.5 gm base/vial Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047. ANDA 207919 Acyclovir Sodium injectable, EQ 50 mg base/mL Dr. Reddy's Laboratories, Inc., 107 College Rd. East, Princeton, NJ 08540. ANDA 209708 Mivacurium Chloride solution, EQ 10 mg base/5 mL (EQ 2 mg base/mL) and EQ 20 mg base/10 mL (EQ 2 mg base/mL) Woodward Pharma Services, LLC.
Document Information
- Published:
- 09/19/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2024-21432
- Dates:
- Approval is withdrawn as of October 21, 2024.
- Pages:
- 76849-76849 (1 pages)
- Docket Numbers:
- Docket No. FDA-2024-N-4289
- PDF File:
- 2024-21432.pdf